Safety and immunogenicity of an oral, replicating adenovirus serotype 4 vector vaccine for H5N1 influenza: a randomised, double-blind, placebo-controlled, phase 1 study
Top Cited Papers
Open Access
- 29 January 2013
- journal article
- research article
- Published by Elsevier in The Lancet Infectious Diseases
- Vol. 13 (3) , 238-250
- https://doi.org/10.1016/s1473-3099(12)70345-6
Abstract
No abstract availableKeywords
This publication has 51 references indexed in Scilit:
- Rapid Immunization Against H5N1: A Randomized Trial Evaluating Homologous and Cross-Reactive Immune Responses to AS03A-Adjuvanted Vaccination in AdultsThe Journal of Infectious Diseases, 2011
- Memory T-Cell Immune Response in Healthy Young Adults Vaccinated with Live Attenuated Influenza A (H5N2) VaccineClinical and Vaccine Immunology, 2011
- An open label Phase I trial of a live attenuated H6N1 influenza virus vaccine in healthy adultsVaccine, 2011
- Novel adenovirus vector-based vaccines for HIV-1Current Opinion in HIV and AIDS, 2010
- Recipients of Vaccine against the 1976 “Swine Flu” Have Enhanced Neutralization Responses to the 2009 Novel H1N1 Influenza VirusClinical Infectious Diseases, 2010
- Vaccination with ALVAC and AIDSVAX to Prevent HIV-1 Infection in ThailandNew England Journal of Medicine, 2009
- A live attenuated H7N3 influenza virus vaccine is well tolerated and immunogenic in a Phase I trial in healthy adultsVaccine, 2009
- A Live Attenuated H9N2 Influenza Vaccine Is Well Tolerated and Immunogenic in Healthy AdultsThe Journal of Infectious Diseases, 2009
- Correlation of Cellular Immune Responses with Protection against Culture-Confirmed Influenza Virus in Young ChildrenClinical and Vaccine Immunology, 2008
- Replicating and non-replicating viral vectors for vaccine developmentCurrent Opinion in Biotechnology, 2007